CSBio CSBio

X
[{"orgOrder":0,"company":"iX Biopharma","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$9.0 million","newsHeadline":"Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SINGAPORE","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"iX Biopharma"},{"orgOrder":0,"company":"Moleac","sponsor":"National University Hospital Singapore","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroAiD(TM)II Holds Promise as a Safe Add-on Therapy to Standard Alzheimer Disease Symptomatic Treatments and May Have a Disease Modifying Effect by Delaying Disease Progression","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Moleac"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            ATHENE study results support the benefit of NeuroAiD™II (MLC901) as a safe add-on therapy to standard AD treatment as the study found no evidence of a significant increase in adverse events between MLC901 and placebo.

            Lead Product(s): MLC901

            Therapeutic Area: Neurology Product Name: NeuroAiD II

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: National University Hospital Singapore

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement with Seelos Therapeutics, has acquired a worldwide license from iX Biopharma for Wafermine™, a sublingual racemic ketamine wafer, and a worldwide license for other sublingual ketamine wafers, delivered using a technology known as WaferiX™.

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Neurology Product Name: Wafermine

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Seelos Therapeutics

            Deal Size: Undisclosed Upfront Cash: $9.0 million

            Deal Type: Acquisition November 24, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY